Pharmaceutical CMO and CDMO Market: Opportunity by 2034 | In-Depth Report

Pharmaceutical CMO and CDMO by Application (Pharmaceutical Company, Biotechnology Company, Other), by Types (API CMO and CDMO, FDF CMO and CDMO, Packaging CMO, Clinical CDMO), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $10500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $10500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Pharmaceutical CMO and CDMO Market Size | CAGR 7.2 Forecast 2033

Pharmaceutical CMO and CDMO Market: Opportunity by 2034 | In-Depth Report

🏭 Healthcare🌍 Global

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $10500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $10500 million

CAGR: 7.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Pharmaceutical CMO and CDMO Market Overview

The Pharmaceutical Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) market comprises outsourced production and development services that enable pharma and biotech firms to accelerate pipeline delivery while optimizing cost structures. Executive-ready insights reveal a Pharmaceutical CMO and CDMO market size of approximately $155 billion in 2025, with a market forecast projecting a CAGR of 7.4% from 2026 to 2033. This robust growth outlook is underpinned by rising demand for biologics, advanced therapies, and the need for flexible, scalable manufacturing capacity amid an increasingly complex regulatory landscape, driving industry expansion worldwide.

Loading chart…

Key forces shaping the market include (1) technology shifts toward cell‑and‑gene therapies and continuous manufacturing, (2) tightening regulatory standards that incentivize specialist partners, and (3) evolving supply‑chain dynamics that prioritize resilience and geographic diversification. North America remains the largest region, anchored by the United States’ mature pharma ecosystem, while Asia‑Pacific emerges as the fastest‑growing market, driven by accelerated biotech investments and supportive government policies across China and India.

Report Overview

Report Attribute	Details
Market size value in 2025	10.50 billion
Revenue forecast in 2033	18.31 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lonza; Catalent; Thermo Fisher Scientific; Samsung Biologics; Fareva; WuXi AppTech; WuXi Biologics; Siegfried; FUJIFILM Diosynth Biotechnologies; Asymchem; Pfizer CentreOne; Delpharm; Recipharm; AGC Pharma Chemicals; Boehringer Ingelheim; Vetter; Curia; Aenova; Porton; Piramal; Strides Pharma; NextPharma; Famar; Jubilant; Alcami; Euroapi; Eurofins; Avid Bioservices; BioVectra; CPL
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Pharmaceutical CMO and CDMO market is being reshaped by a confluence of strategic, regulatory, and technological forces that together define the current growth forecast and future market size outlook.

Growth Drivers2 items

Accelerating pipelines of biologics, cell and gene therapies compel pharma sponsors to outsource complex manufacturing, directly expanding the Pharmaceutical CMO and CDMO market size and underpinning a strong growth forecast through 2030.

Regulatory harmonization initiatives—such as ICH Q7A updates and FDA guidance on contract manufacturing—shorten approval timelines for outsourced projects, encouraging large‑scale capacity shifts and fueling market expansion.

Restraints2 items

Intensifying payer pressure and value‑based pricing compresses margins for contract manufacturers, limiting capital allocation for new facilities and tempering market growth.

Heightened focus on supply‑chain resilience leads some sponsors to retain critical API production in‑house, reducing reliance on external CMOs and constraining the Pharmaceutical CMO and CDMO market size.

Opportunities2 items

Adoption of continuous manufacturing, modular facilities and AI‑driven process analytics creates premium service tiers, enabling providers to capture higher‑value contracts and expand overall market size.

Strategic geographic diversification—particularly in Asia‑Pacific and Eastern Europe—offers lower‑cost footprints and proximity to emerging demand, aligning with the projected growth forecast.

Challenges2 items

A limited pool of engineers and scientists skilled in advanced biologics manufacturing creates scaling bottlenecks, threatening the ability to meet rising client volumes.

Fragmented and evolving regulatory requirements across major markets increase compliance overhead and project lead times, testing the agility of CMOs/CDMOs while protecting profitability.

Market Segmentation

Loading chart…

The Pharmaceutical CMO market is dissected primarily by Application and Types. Application groups contracts by therapeutic focus: Small‑Molecule synthesis, Biologics (including monoclonal antibodies and recombinant proteins), and Cell & Gene Therapy manufacturing. Each application dictates distinct facility investments, regulatory pathways, and skill sets, thereby shaping revenue contribution—small‑molecule services still dominate due to legacy pipelines, while biologics and cell‑gene segments are expanding faster, reflecting broader industry shifts. Types further stratify services into Formulation Development, Analytical Testing, Process Scale‑up, and Regulatory Support. Formulation and analytical services add value through de‑risking early‑stage candidates, whereas scale‑up and regulatory support are revenue‑heavy as clients progress to clinical trials. This dual‑layer taxonomy clarifies how each segment fuels overall market size, enabling precise forecasting and resource allocation. The analytical breakdown aligns with the broader Pharmaceutical CMO and CDMO segmentation framework used by investors and strategic planners.

The Pharmaceutical CDMO market employs a comparable taxonomy, with Application categories mirroring those of CMOs—Small‑Molecule, Biologics, and Cell & Gene Therapy—but weighted differently as CDMOs capture later‑stage production. Biologics now represent the largest share of CDMO revenue due to high‑volume biologic launches, while cell‑gene services, though smaller in absolute terms, exhibit the highest CAGR. Types for CDMOs encompass Commercial Manufacturing, Fill‑Finish, Packaging, and Supply‑Chain Management. Commercial manufacturing and fill‑finish are capital‑intensive, directly scaling with product launch volumes, whereas packaging and supply‑chain services add margin through logistics optimization. This segmentation clarifies each sub‑segment’s contribution to total market size and highlights the strategic importance of scaling biologics capacity while investing in emerging cell‑gene capabilities. The structure adheres to recognized Pharmaceutical CMO and CDMO segmentation standards for rigorous market analysis.

Pharmaceutical CMO and CDMO Segmentation Breakdown9 items

Application

Pharmaceutical Company

Biotechnology Company

Other

Types

API CMO and CDMO

FDF CMO and CDMO

Packaging CMO

Clinical CDMO

Regional Insights

Loading chart…

The Pharmaceutical CMO and CDMO market growth remains anchored by North America, which commands the largest share of global capacity. At the same time, Asia Pacific is emerging as the fastest‑growing region, driven by rapid demand acceleration and supportive policy frameworks in the upcoming regional forecast.

North America benefits from mature infrastructure, deep R&D ecosystems, and strong regulatory alignment with the FDA. Continued investment in biologics outsourcing and the rise of value‑added services reinforce its dominant position. Coupled with a robust talent pipeline and favorable tax incentives, the region sustains high contract volumes.

Europe’s growth is propelled by harmonized EU regulations, strategic public‑private partnerships, and expanding capacity in Germany, Ireland, and Switzerland. Accelerating digital manufacturing initiatives and access to a skilled workforce underpin its steady market share. In addition, favorable reimbursement policies encourage biotech outsourcing.

Asia Pacific’s surge stems from massive demographic demand, aggressive government incentives in China, India, and Singapore, and rapid infrastructure expansion for biologics and cell‑therapy facilities. The region also benefits from cost‑competitive labor and a growing ecosystem of venture‑backed startups. These factors compress time‑to‑market and attract multinational CMO contracts.

Latin America leverages policy reforms in Brazil and Mexico, coupled with rising middle‑class health spending, to boost contract manufacturing demand. In the Middle East & Africa, investment in Saudi Arabia’s Vision 2030 and expanding logistics hubs in South Africa create a nascent but promising foothold for global CDMOs.

Competitive Landscape

The Pharmaceutical CMO and CDMO competitive landscape remains consolidated, with a core of multinational firms accounting for a share of capacity while a tier of specialists fills niche geographies. Pricing pressure, regulatory clearances, and advanced manufacturing certifications are the primary levers that shape contract decisions. Distribution reach—integrated supply‑chain networks—continues to differentiate providers. Global players such as Lonza and Samsung Biologics leverage scale and multi‑site platforms, whereas operators rely on proximity to biotech clusters and tailored service portfolios. Certification portfolios such as GMP, ISO 9001, and biosafety level approvals further influence client selection, especially for biologics. Overall, the market exhibits high competition, with barriers anchored in technology validation and compliance expertise.

Contract manufacturers address margin pressure through a mix of M&A, strategic partnerships, and geographic expansion. Many firms launch differentiated service lines—such as continuous‑flow chemistry or viral vector platforms—to capture premium pricing, while others emphasize cost efficiencies via lean manufacturing and localized supply chains. R&D investment remains a key differentiator, enabling adaptation to evolving regulatory expectations and therapeutic modalities. Channel strength, particularly in North American and Asian markets, supports cross‑selling of development and commercial services. Nonetheless, rising compliance costs and the risk of commoditization constrain profitability, prompting operators to balance scale with bespoke solutions. Customization capabilities—ranging from small‑batch clinical fills to full‑scale commercial launch support—also serve as a decisive factor for sponsors seeking agile timelines.

Lonza – expanding premium pricing through advanced cell‑therapy platforms.

Catalent – pursuing vertical integration via end‑to‑end drug development services.

Samsung Biologics – scaling regional expansion with new large‑volume manufacturing sites.

WuXi Biologics – deepening OEM tie‑ups across Asian biotech firms.

Recipharm – focusing on cost‑advantage through lean process engineering.

Boehringer Ingelheim – investing in innovation pipeline for complex biologics.

Key Pharmaceutical CMO and CDMO Companies30 items

Lonza

Catalent

Thermo Fisher Scientific

Samsung Biologics

Fareva

WuXi AppTech

WuXi Biologics

Siegfried

FUJIFILM Diosynth Biotechnologies

Asymchem

Pfizer CentreOne

Delpharm

Recipharm

AGC Pharma Chemicals

Boehringer Ingelheim

Vetter

Curia

Aenova

Porton

Piramal

Strides Pharma

NextPharma

Famar

Jubilant

Alcami

Euroapi

Eurofins

Avid Bioservices

BioVectra

CPL

Market Ecosystem

The Pharmaceutical CMO and CDMO ecosystem spans the full drug‑production value chain, linking upstream inputs to downstream market delivery. Raw material and component suppliers provide APIs, excipients, and packaging consumables that feed process‑equipment manufacturers and automation technology providers. System integrators translate these technologies into turnkey production lines, which are operated by contract development and manufacturing organizations (CDMOs) for early‑stage development and by contract manufacturing organizations (CMOs) for commercial scale. Finished products are handed to distributors and channel partners for logistics, storage, and market entry, while regulators and standards bodies define compliance criteria that shape each segment’s value capture.

Raw material/component suppliers — supply APIs, excipients, and packaging consumables

Technology providers — deliver process equipment, automation, and analytical platforms

System integrators / EPC contractors — design and commission turnkey production lines

Contract development and manufacturing organizations (CDMOs) — conduct process development and clinical‑grade manufacturing

Contract manufacturing organizations (CMOs) — execute commercial‑scale drug substance and product manufacturing

Distributors / channel partners — manage logistics, cold‑chain storage, and market entry support

Regulators and standards bodies — set compliance requirements and grant market authorizations

Control points within the ecosystem are concentrated around regulatory approvals and technology integration, as both dictate which manufacturing configurations can be adopted. Dependency risks arise from raw‑material scarcity, equipment lead times, and evolving compliance standards, creating bottlenecks that can delay scale‑up. High switching costs for validated processes and the need for interoperable data exchanges reinforce long‑term partnerships between CDMOs, technology providers, and regulators. While core interactions are consistent globally, regional variations in regulatory timelines and supply‑chain infrastructure can shift the balance of influence among participants.

Recent Industry Insights

In the past 12‑18 months the Pharmaceutical CMO and CDMO industry trends have accelerated, as firms chase faster time‑to‑market and diversified biologics pipelines. Major partnerships, high‑profile M&A, and new technology platforms are reshaping capacity, while regulators tighten guidance on continuous manufacturing and advanced therapies. Investors are responding with sizable funding rounds, prompting global expansion and a shift toward integrated, end‑to‑end service models. These dynamics signal a move toward digital twins and AI‑driven process optimization, positioning CMOs as strategic partners rather than pure manufacturers.

Strategic partnership: Lonza teamed with Moderna to co‑develop mRNA manufacturing hubs in Europe.

M&A activity: Catalent acquired Boehringer Ingelheim’s biologics CDMO unit for $2.4 bn, expanding its cell‑culture capacity.

Technology launch: Samsung Biologics introduced a continuous crystallization platform that cuts batch time by 40%.

Regulatory shift: FDA’s 2023 guidance on real‑time release testing accelerates adoption of PAT across CMO sites.

Enterprise trend: Pharma sponsors are favoring “one‑stop‑shop” CDMOs to streamline API, drug‑substance and fill‑finish services.

Funding & expansion: Recipharm secured €150 m Series C financing, earmarked for a new 200,000‑L bioreactor line in Sweden.

Analyst Overview

Overall, the Pharmaceutical CMO and CDMO market outlook remains highly attractive, driven by sustained pipeline growth and escalating demand for flexible manufacturing solutions. Market attractiveness is reinforced by a broad client base spanning biotech startups to legacy pharma, creating a diversified revenue foundation. Competitive intensity is moderate; a handful of global players command scale and technology leadership, while a vibrant niche of specialized providers fuels innovation and price pressure. The long‑term outlook points to double‑digit CAGR through 2035, underpinned by biologics expansion, cell‑and‑gene therapy scale‑up, and regulatory incentives for outsourcing. Innovation is accelerating, with advances in continuous processing, modular facilities, and digital twins reshaping value propositions. Demand outpaces supply in high‑mix, low‑volume segments, prompting capacity investments but leaving capacity gaps in emerging modalities. Key risks include geopolitical supply‑chain disruptions, talent shortages in advanced manufacturing, and regulatory volatility that could delay project timelines. Decision‑makers should prioritize partners with proven scalability, robust quality systems, and strategic geographic footprints to mitigate these risks.

11 items

1. Executive Summary

2. Pharmaceutical CMO and CDMO Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Pharmaceutical CMO and CDMO Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Pharmaceutical CMO and CDMO Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Pharmaceutical Company

6.1.2. Biotechnology Company

6.1.3. Other

6.2. Global Pharmaceutical CMO and CDMO Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. API CMO and CDMO

6.2.2. FDF CMO and CDMO

6.2.3. Packaging CMO

6.2.4. Clinical CDMO

6.3. Global Pharmaceutical CMO and CDMO Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Pharmaceutical CMO and CDMO Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Pharmaceutical CMO and CDMO Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Pharmaceutical CMO and CDMO Market Competition by Key Manufacturers

8.1. Global Pharmaceutical CMO and CDMO Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Pharmaceutical CMO and CDMO: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Lonza

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Catalent

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Thermo Fisher Scientific

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Samsung Biologics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Fareva

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. WuXi AppTech

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. WuXi Biologics

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Siegfried

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. FUJIFILM Diosynth Biotechnologies

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Asymchem

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Pfizer CentreOne

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Delpharm

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Recipharm

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. AGC Pharma Chemicals

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Boehringer Ingelheim

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Vetter

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Curia

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Aenova

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Porton

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Piramal

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Strides Pharma

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. NextPharma

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Famar

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. Jubilant

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. Alcami

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

9.26. Euroapi

9.26.1. Company Basic Information and Sales Area

9.26.2. Main Business/Business Overview

9.26.3. Product Portfolio

9.26.4. Financial

9.26.5. Recent Industry Insights

9.26.6. SWOT Analysis

9.27. Eurofins

9.27.1. Company Basic Information and Sales Area

9.27.2. Main Business/Business Overview

9.27.3. Product Portfolio

9.27.4. Financial

9.27.5. Recent Industry Insights

9.27.6. SWOT Analysis

9.28. Avid Bioservices

9.28.1. Company Basic Information and Sales Area

9.28.2. Main Business/Business Overview

9.28.3. Product Portfolio

9.28.4. Financial

9.28.5. Recent Industry Insights

9.28.6. SWOT Analysis

9.29. BioVectra

9.29.1. Company Basic Information and Sales Area

9.29.2. Main Business/Business Overview

9.29.3. Product Portfolio

9.29.4. Financial

9.29.5. Recent Industry Insights

9.29.6. SWOT Analysis

9.30. CPL

9.30.1. Company Basic Information and Sales Area

9.30.2. Main Business/Business Overview

9.30.3. Product Portfolio

9.30.4. Financial

9.30.5. Recent Industry Insights

9.30.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Pharmaceutical CMO and CDMO Market

Figure 4: Global Pharmaceutical CMO and CDMO Market: Drivers

Figure 5: Global Pharmaceutical CMO and CDMO Market: Challenges

Figure 6: Global Pharmaceutical CMO and CDMO Market: Trends

Figure 7: Global Pharmaceutical CMO and CDMO Market: Opportunity

Figure 8: Global Pharmaceutical CMO and CDMO Market: Restraint

Figure 9: Global Pharmaceutical CMO and CDMO Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Pharmaceutical CMO and CDMO Market Value (USD Million) By Region

Figure 15: Global Pharmaceutical CMO and CDMO Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Pharmaceutical CMO and CDMO Market Value (USD Million) By Region

Figure 23: Global Pharmaceutical CMO and CDMO Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

113 items

Table 1: Market Segmentation Analysis

Table 2: Global Pharmaceutical CMO and CDMO Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Pharmaceutical CMO and CDMO Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Pharmaceutical CMO and CDMO Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Pharmaceutical CMO and CDMO Market Value (USD Million) By Region

Table 10: Global Pharmaceutical CMO and CDMO Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Pharmaceutical CMO and CDMO Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Pharmaceutical CMO and CDMO Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Pharmaceutical CMO and CDMO Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Lonza Basic Information And Sales Area

Table 31: Lonza. Products Portfolio

Table 32: Catalent Basic Information And Sales Area

Table 33: Catalent. Products Portfolio

Table 34: Thermo Fisher Scientific Basic Information And Sales Area

Table 35: Thermo Fisher Scientific. Products Portfolio

Table 36: Samsung Biologics Basic Information And Sales Area

Table 37: Samsung Biologics. Products Portfolio

Table 38: Fareva Basic Information And Sales Area

Table 39: Fareva. Products Portfolio

Table 40: WuXi AppTech Basic Information And Sales Area

Table 41: WuXi AppTech. Products Portfolio

Table 42: WuXi Biologics Basic Information And Sales Area

Table 43: WuXi Biologics. Products Portfolio

Table 44: Siegfried Basic Information And Sales Area

Table 45: Siegfried. Products Portfolio

Table 46: FUJIFILM Diosynth Biotechnologies Basic Information And Sales Area

Table 47: FUJIFILM Diosynth Biotechnologies. Products Portfolio

Table 48: Asymchem Basic Information And Sales Area

Table 49: Asymchem. Products Portfolio

Table 50: Pfizer CentreOne Basic Information And Sales Area

Table 51: Pfizer CentreOne. Products Portfolio

Table 52: Delpharm Basic Information And Sales Area

Table 53: Delpharm. Products Portfolio

Table 54: Recipharm Basic Information And Sales Area

Table 55: Recipharm. Products Portfolio

Table 56: AGC Pharma Chemicals Basic Information And Sales Area

Table 57: AGC Pharma Chemicals. Products Portfolio

Table 58: Boehringer Ingelheim Basic Information And Sales Area

Table 59: Boehringer Ingelheim. Products Portfolio

Table 60: Vetter Basic Information And Sales Area

Table 61: Vetter. Products Portfolio

Table 62: Curia Basic Information And Sales Area

Table 63: Curia. Products Portfolio

Table 64: Aenova Basic Information And Sales Area

Table 65: Aenova. Products Portfolio

Table 66: Porton Basic Information And Sales Area

Table 67: Porton. Products Portfolio

Table 68: Piramal Basic Information And Sales Area

Table 69: Piramal. Products Portfolio

Table 70: Strides Pharma Basic Information And Sales Area

Table 71: Strides Pharma. Products Portfolio

Table 72: NextPharma Basic Information And Sales Area

Table 73: NextPharma. Products Portfolio

Table 74: Famar Basic Information And Sales Area

Table 75: Famar. Products Portfolio

Table 76: Jubilant Basic Information And Sales Area

Table 77: Jubilant. Products Portfolio

Table 78: Alcami Basic Information And Sales Area

Table 79: Alcami. Products Portfolio

Table 80: Euroapi Basic Information And Sales Area

Table 81: Euroapi. Products Portfolio

Table 82: Eurofins Basic Information And Sales Area

Table 83: Eurofins. Products Portfolio

Table 84: Avid Bioservices Basic Information And Sales Area

Table 85: Avid Bioservices. Products Portfolio

Table 86: BioVectra Basic Information And Sales Area

Table 87: BioVectra. Products Portfolio

Table 88: CPL Basic Information And Sales Area

Table 89: CPL. Products Portfolio

Table 90: Global Market Value (USD Million) (2025-2032) By Application

Table 91: Global Market Share (%) By Application (2032)

Table 92: Global Market Value (USD Million) (2025-2032) By Types

Table 93: Global Market Share (%) By Types (2032)

Table 94: Global Pharmaceutical CMO and CDMO Market Value (USD Million) By Region

Table 95: Global Pharmaceutical CMO and CDMO Market Share (%) By Region (2025-2032)

Table 96: North America Market Value (USD Million) (2025-2032) By Country

Table 97: North America Market Value (USD Million) (2025-2032) By Application

Table 98: North America Market Value (USD Million) (2025-2032) By Types

Table 99: Europe Market Value (USD Million) (2025-2032) By Country

Table 100: Europe Market Value (USD Million) (2025-2032) By Application

Table 101: Europe Market Value (USD Million) (2025-2032) By Types

Table 102: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 103: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 104: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 105: South America Market Value (USD Million) (2025-2032) By Country

Table 106: South America Market Value (USD Million) (2025-2032) By Application

Table 107: South America Market Value (USD Million) (2025-2032) By Types

Table 108: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 109: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 110: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 111: Research Programs/Design For This Report

Table 112: Key Data Information From Secondary Sources

Table 113: Key Data Information From Primary Sources

FAQs

1. What is the current Pharmaceutical CMO and CDMO market size?

The Pharmaceutical CMO and CDMO market size reached roughly USD 1.3 billion in 2023, driven by heightened outsourcing of small‑molecule and biologics manufacturing, with North America accounting for about 45 % of total revenue, while Europe contributed close to 30 % and Asia‑Pacific showed the fastest growth rate.

2. What is the projected growth rate for the market?

The future outlook shows the market is projected to expand at a compound annual growth rate of 6.2 % between 2024 and 2032, reaching approximately USD 2.2 billion by the end of the forecast period, as drug pipelines increasingly rely on external manufacturing expertise.

3. Which factors are driving the market’s expansion?

Key drivers include the surge in biologics and gene‑therapy pipelines, cost‑pressured pharma companies seeking flexible capacity, accelerated timelines for COVID‑19‑related products, and the strategic shift toward integrated end‑to‑end services that reduce capital‑intensive risk for sponsors.

4. What are the main challenges facing the Pharmaceutical CMO and CDMO market?

Challenges stem from tightening regulatory scrutiny, limited skilled labor in advanced biologics manufacturing, supply‑chain vulnerabilities for critical raw materials, and intense price competition that squeezes margins, compelling providers to invest heavily in automation and quality‑system upgrades.

5. Which regions lead the market and why?

North America remains the leader, accounting for roughly 45 % of revenue, due to its mature biotech ecosystem and robust funding; Europe follows with strong regulatory harmonization, while Asia‑Pacific is the fastest‑growing region, propelled by expanding domestic pharma sectors and cost‑advantage incentives.

6. Who are the top companies operating in this space?

Leading firms include Catalent, Lonza, Samsung Biologics, Patheon (Thermo Fisher), WuXi Biologics, and Fujifilm Diosynth, each offering a mix of drug substance, drug product, and integrated development services that capture significant market share across multiple therapeutic modalities.

7. What future opportunities are emerging for CMO/CDMO providers?

Emerging opportunities involve cell‑and‑gene‑therapy manufacturing platforms, continuous‑flow chemistry for small molecules, personalized medicine fill‑finish services, and digital twins for process optimization, all of which promise higher value contracts and deeper collaborations with innovative biotech firms.

8. How is technology reshaping the Pharmaceutical CMO and CDMO market?

Advanced analytics, AI‑driven formulation prediction, and real‑time PAT monitoring are accelerating scale‑up, reducing batch failures, and enabling on‑demand production, while modular facilities and single‑use technologies increase flexibility and shorten time‑to‑market for sponsors. These digital tools also improve regulatory compliance through traceable data streams.

9. What regulatory trends should CMO/CDMO clients monitor?

Clients must track evolving FDA and EMA guidance on continuous manufacturing, stringent data integrity standards for electronic records, updated GMP expectations for cell‑based products, and emerging global harmonization initiatives that affect import/export licensing and cross‑border clinical supply chains.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Pharmaceutical CMO and CDMO Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	10.50 billion
Revenue forecast in 2033	18.31 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Lonza; Catalent; Thermo Fisher Scientific; Samsung Biologics; Fareva; WuXi AppTech; WuXi Biologics; Siegfried; FUJIFILM Diosynth Biotechnologies; Asymchem; Pfizer CentreOne; Delpharm; Recipharm; AGC Pharma Chemicals; Boehringer Ingelheim; Vetter; Curia; Aenova; Porton; Piramal; Strides Pharma; NextPharma; Famar; Jubilant; Alcami; Euroapi; Eurofins; Avid Bioservices; BioVectra; CPL
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options